THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without a prior history of heart attack or stroke. This comes several weeks after ...

On the heels of an FDA label expansion in August, Amgen is touting another potential avenue to extend the value of its decade-old PCSK9 cholesterol med Repatha. In the late-stage Vesalius-CV study, ...

Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When reporting ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

Repatha is the first and only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention. The results were presented in a ...